Table 1.
Demographics and clinical characteristics of COVID‐19 patients
| Acute COVID‐19 |
Convalescent COVID‐19 5 months |
Convalescent COVID‐19 9 months |
||||
|---|---|---|---|---|---|---|
| Moderate | Severe | Moderate | Severe | Moderate | Severe | |
| Total n | 10 | 16 | 8 | 9 | 8 | 5 |
| Age, years, median (range) | 57 (18–76) | 58 (40–74) | 58 (34–76) | 56 (40–63) | 58 (34–76) | 61 (45–63) |
| Male, n | 7 | 13 | 7 | 6 | 7 | 4 |
| Female, n | 3 | 3 | 1 | 3 | 1 | 1 |
| Symptom onset to sampling, days, median (range) | 14 (6–19) | 14 (5–24) | 155 (144–171) | 155 (142–172) | 274 (264–287) | 278 (263–284) |
| Total duration of hospitalisation, median days (range) | 8 (5–39) | 19 (10–138) | 8 (5–39) | 17 (10–57) | 8 (5–39) | 15 (10–49) |
| At least one comorbidity a , n | 6 | 11 | 6 | 6 | 6 | 4 |
| Fatal outcome, n | 0 | 4 | 0 | 0 | 0 | 0 |
| Peak supplemental oxygen treatment | ||||||
| No oxygen, n | 2 | 0 | 1 | 0 | 1 | 0 |
| Low flow, n | 7 | 3 | 6 | 3 | 6 | 2 |
| High flow, n | 1 | 0 | 1 | 0 | 1 | 0 |
| Mechanical ventilation/ECMO, n | 0 | 13 | 0 | 6 | 0 | 3 |
| Treatment | ||||||
| ICU treatment, n | 0 | 16 | 0 | 9 | 0 | 5 |
| Steroids before acute sampling, n | 2 | 11 | 2 | 5 | 2 | 3 |
| Antibiotics before acute sampling, n | 3 | 11 | 2 | 6 | 2 | 3 |
| Anticoagulants before acute sampling, n | 10 | 14 | 8 | 9 | 8 | 5 |
| Specific treatment before acute sampling b , c , n | 0 | 2 b , c | 0 | 1 b | 0 | 1 b |
ECMO, extracorporeal membrane oxygenation; ICU, intensive care unit.
a
Hypertension, type II diabetes, asthma, obesity, obstructive sleep apnoea syndrome, chronic hepatitis B infection, coronary heart disease.
b
Remdesivir.
c
Tocilizumab.